Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

A Phase 3 trial investigating perifosine in combination with bortezomib (VELCADE®) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma is expected to commence by year-end under a Special Protocol Assessment (SPA) with the FDA. In addition, in September, the Company announced that perifosine had received Orphan-Drug designation in the United States for the treatment of multiple myeloma.

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "This Fast Track designation can significantly reduce the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma." Mr. Bentsur added, "We believe that the Fast Track designation, together with the SPA and Orphan Drug status previously granted to us by the FDA for perifosine in multiple myeloma, significantly enhances the value proposition of perifosine in this indication. We are eager to begin the Phase 3 trial later this month."

KRX-0401 (perifosine) is in-licensed by
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., ... therapeutics, including those with rare and orphan inflammatory disease ... the U.S. Food and Drug Administration (FDA) to begin ... candidate, acebilustat (CTX-4430), in adult CF patients in the ... Europe will be filed soon ...
(Date:7/6/2015)... FRANCISCO, Calif. , July 6, 2015 ... pharmaceutical company, and Oculeve, a development-stage medical device company ... today announced that they have entered into an agreement ... transaction.  Under the terms of the agreement, Allergan will ... commercialization milestone payments related to Oculeve,s lead development program ...
(Date:7/6/2015)... , July 6, 2015 China Information Technology, Inc. ... provider of integrated cloud-based platform, exchange, and big data ... that the Company launched its mobile app for Healthcare ... healthcare services on mobile devices. The Company jointly hosted ... Family Planning Bureau and Shenzhen News Net.   ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... Naviscan, Inc., the worldwide leader in 3D Molecular ... PhD has joined the Naviscan Board of Directors. ... related to reimbursement in the medical device industry.  He ... Reimbursement at Acclarent, Inc.  After acquisition by Ethicon, Inc., ...
... Calif., July 14, 2011 Molecular Devices, LLC, ... & development, life science research, and bioassay/test development, ... Accreditation (A2LA) has accredited the Laboratory Quality System ... re-calibration processes. (Logo: http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ...
Cached Medicine Technology:Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng 2Molecular Devices Continues to Lead the Way in Quality Control and Validation Compliance With a New ISO/IEC 17025 Accreditation 2
(Date:7/4/2015)... ... July 04, 2015 , ... Chronic Neck Pain. Neck pain is ... located in the neck. Another 19% suffer from head, migraine, or facial pain, in ... that 45% of American workers must deal with neck pain. Strategies for ...
(Date:7/3/2015)... ... , ... The Harvest Hope Food Bank will hopefully be getting a large donation ... in the area of Greenville SC are making it their mission to collect as many ... are asking for donations from the public as well. As part of the canned food ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Smoothies are ... is a good blender and easily accessible, quality ingredients. Aurora Natural is proud to ... for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
... Western society are suffering from auto-immune diseases. Discovering the ... step in the search for targeted medicines. VIB researchers ... joined forces and have elucidated the function of MALT1, ... are the first to show that MALT1 is able ...
... rumi regulates Notch signaling by adding a glucose molecule ... outside a cell, said researchers from Baylor College of ... York in a report that appears today in the ... protein determines cell fate determination and differentiation. , ...
... Comment, ROLLING MEADOWS, Ill., Jan. 26 ... member specialty,organization of leaders in the field of ... the petition filed by Public Citizen with the,U.S. ... The ASDS supports the current labeling of all ...
... 25 The,American Society of Plastic Surgeons (ASPS) ... products and adverse events following,a recent petition from ... Citizen requested the U.S. Food and Drug,Administration (FDA) ... More than one million people have been ...
... Costs have climbed 32% since 2002, study finds ... and economic costs in the United States hit $174 ... a new study shows. , The research, commissioned by ... for people with diabetes were about $116 billion, and ...
... attempt to end own life, study finds , , FRIDAY, Jan. 25 ... likely to attempt suicide and more than twice as likely to ... study says. , Violent suicide includes hanging, the use of a ... of a vehicle, or drowning. , The increased risk of suicide ...
Cached Medicine News:Health News:A major step toward a more targeted treatment for auto-immune diseases? 2Health News:Notch-ing glucose into place 2Health News:American Society for Dermatologic Surgery Supports Current Labeling of Allergan's Botox(R) Products 2Health News:ASPS Addresses Concerns Regarding BOTOX Treatments 2Health News:Diabetes' Health Toll Hits $174 Billion Annually 2Health News:Short Birth Length Boosts Men's Suicide Risk 2
9 mm wide tip. Designated most popular model or size....
4 mm wide tip. Designated most popular model or size....
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Designated most popular model or size. 4 mm wide tip....
Medicine Products: